Les thérapies antisens en neurologie

BrunetdeCourssou, 2023, Les thérapies géniques en neurologie, Prat Neurol FMC, 14, 1 Shen, 2018, Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs, Nucleic Acids Res, 46, 1584, 10.1093/nar/gkx1239 Bennett, 2017, Pharmacology of antisense drugs, Annu Rev Pharmacol Toxicol, 57, 81, 10.1146/annurev-pharmtox-010716-104846 Kordasiewicz, 2012, Sustained therapeutic reversal of Huntington's disease by transient repression of Huntington synthesis, Neuron, 74, 1031, 10.1016/j.neuron.2012.05.009 Pattali, 2019, AAV9 Vector: a novel modality in gene therapy for spinal muscular atrophy, Gene Ther, 26, 287, 10.1038/s41434-019-0085-4 Zou, 2020, Single siRNA nanocapsules for effective siRNA brain delivery and glioblastoma treatment, Adv Mater, 32, 2000416, 10.1002/adma.202000416 Yonezawa, 2020, Recent advances in siRNA delivery mediated by lipid-based nanoparticles, Adv Drug Deliv Rev, 154–155, 64, 10.1016/j.addr.2020.07.022 Balwani, 2020, Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria, N Engl J Med, 382, 2296, 10.1056/NEJMoa1913147 Adams, 2018, Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis, N Engl J Med, 379, 11, 10.1056/NEJMoa1716153 Adams, 2022, Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial, Amyloid, 30, 1 Lee, 2015, Mechanisms and regulation of alternative pre-mRNA splicing, Annu Rev Biochem, 84, 291, 10.1146/annurev-biochem-060614-034316 Hyjek, 2019, RNases H: structure and mechanism, DNA Repair, 84, 102672, 10.1016/j.dnarep.2019.102672 Good, 2003, Translation repression by antisense sequences, Cell Mol Life Sci CMLS, 60, 854, 10.1007/s00018-003-3045-4 Park, 2014, Effect of siRNA with an asymmetric RNA/dTdT Overhang on RNA interference activity, Nucleic Acid Ther, 24, 364, 10.1089/nat.2014.0494 Treiber, 2019, Regulation of microRNA biogenesis and its crosstalk with other cellular pathways, Nat Rev Mol Cell Biol, 20, 5, 10.1038/s41580-018-0059-1 Sheu-Gruttadauria, 2017, Structural foundations of RNA silencing by argonaute, J Mol Biol, 429, 2619, 10.1016/j.jmb.2017.07.018 Wirth, 2020, Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next, Annu Rev Genomics Hum Genet, 21, 231, 10.1146/annurev-genom-102319-103602 Ramdas, 2020, New treatments in spinal muscular atrophy: an overview of currently available data, Expert Opin Pharmacother, 21, 307, 10.1080/14656566.2019.1704732 Butchbach, 2021, Genomic variability in the survival motor neuron genes (SMN1 and SMN2): implications for spinal muscular atrophy phenotype and therapeutics development, Int J Mol Sci, 22, 7896, 10.3390/ijms22157896 Finkel, 2017, Nusinersen versus sham control in infantile-onset spinal muscular atrophy, N Engl J Med, 377, 1723, 10.1056/NEJMoa1702752 Finkel, 2018, Nusinersen versus sham control in later-onset spinal muscular atrophy, N Engl J Med, 378, 625, 10.1056/NEJMoa1710504 Medicines and Healthcare products Regulatory Agency. Drug safety update. Nusinersen (Spinraza): reports of communicating hydrocephalus; discuss symptoms with patients and carers and investigate urgently. GOV.UK. Published September 25, 2018. Accessed December 16, 2020; 2020. https://www.gov.uk/drug-safety-update/nusinersen-spinraza-reports-of-communicating-hydrocephalus-discuss-symptoms-with-patients-and-carers-and-investigate-urgently. Falsaperla, 2019, Intrathecal administration of nusinersen in patients with SMA1: too little is known, Neurol Case Rep, 2, 3 Stoker, 2021, Hydrocephalus complicating intrathecal antisense oligonucleotide therapy for Huntington's Disease, Mov Disord, 36, 263, 10.1002/mds.28359 Rowczenio, 2014, Online registry for mutations in hereditary amyloidosis including nomenclature recommendations, Hum Mutat, 35, E2403, 10.1002/humu.22619 Gertz, 2019, Advances in the treatment of hereditary transthyretin amyloidosis: a review, Brain Behav, 9, 10.1002/brb3.1371 Benson, 2018, Inotersen treatment for patients with hereditary transthyretin amyloidosis, N Engl J Med, 379, 22, 10.1056/NEJMoa1716793 Narayanan, 2020, Underlying immune disorder may predispose some transthyretin amyloidosis subjects to inotersen-mediated thrombocytopenia, Nucleic Acid Ther, 30, 94, 10.1089/nat.2019.0829 Sewing, 2017, Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia. Schulz C, ed, PLoS One, 12, e0187574, 10.1371/journal.pone.0187574 Flierl, 2015, Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators, J Exp Med, 212, 129, 10.1084/jem.20140391 Brannagan, 2020, Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial, Eur J Neurol, 27, 1374, 10.1111/ene.14285 Zhang, 2020, Patisiran pharmacokinetics, pharmacodynamics, and exposure-response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin-mediated (hATTR) amyloidosis, J Clin Pharmacol, 60, 37, 10.1002/jcph.1480 Adams, 2021, Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study, Lancet Neurol, 20, 49, 10.1016/S1474-4422(20)30368-9 1993, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group, Cell, 72, 971, 10.1016/0092-8674(93)90585-E Lee, 2019, CAG repeat not polyglutamine length determines timing of Huntington's disease onset, Cell, 178, 887, 10.1016/j.cell.2019.06.036 Tabrizi, 2019, Targeting Huntingtin expression in patients with Huntington's disease, N Engl J Med, 380, 2307, 10.1056/NEJMoa1900907 Durr, 2019, [Anti-sense oligonucleotides RNA therapy in Huntington disease: a great promise and many unknowns], Med Sci MS, 35, 834 Ionis’ partner to evaluate tominersen for Huntington's disease in new Phase 2 trial | Ionis Pharmaceuticals, Inc.; Accessed June 2, 2022. https://ir.ionispharma.com/news-releases/news-release-details/ionis-partner-evaluate-tominersen-huntingtons-disease-new-phase. Wave Life Sciences. Wave life sciences provides update on phase 1b/2a PRECISION-HD Trials - Wave Life Sciences; Published March 29, 2021. Accessed May 25, 2021. https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-provides-update-phase-1b2a-precision-hd. Patutina, 2020, Mesyl phosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potency, Proc Natl Acad Sci, 117, 32370, 10.1073/pnas.2016158117 Evers, 2011, Targeting several CAG expansion diseases by a single antisense oligonucleotide. Glorioso JC,ed, PLoS One, 6, e24308, 10.1371/journal.pone.0024308 Datson, 2017, The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain. Li Y, ed, PLoS One, 12, e0171127, 10.1371/journal.pone.0171127 Therapeutics V. US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia. VICO Therapeutics. Published June 29, 2021. Accessed October 13, 2022. https://vicotx.com/us-fda-grants-vico-therapeutics-orphan-drug-designation-for-vo659-an-investigational-therapy-for-spinocerebellar-ataxia/. Coarelli, 2018, Recent advances in understanding dominant spinocerebellar ataxias from clinical and genetic points of view, F1000Research, 7 Kotowska-Zimmer, 2020, Universal RNAi triggers for the specific inhibition of mutant Huntington, Atrophin-1, Ataxin-3, and Ataxin-7 Expression, Mol Ther Nucleic Acids, 19, 562, 10.1016/j.omtn.2019.12.012 Fiszer, 2012, An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases, BMC Mol Biol, 13, 6, 10.1186/1471-2199-13-6 uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress | uniqure BV. Accessed October 13, 2022. https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2022-financial-results-and. Pfizer to Open First U.S. Sites in Phase 3 Trial of Investigational Gene Therapy for ambulatory patients with Duchenne muscular Dystrophy | Pfizer. Accessed May 24, 2022. https://ww.pfizer.com/news/press-release/press-release-detail/pfizer-open-first-us-sites-phase-3-trial-investigational. Lopez, 2022, New antisense oligonucleotide therapies reach first base in ALS, Nat Med, 28, 25, 10.1038/s41591-021-01629-7 Cirak, 2011, Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study, Lancet Lond Engl, 378, 595, 10.1016/S0140-6736(11)60756-3 Mendell, 2013, Eteplirsen for the treatment of Duchenne muscular dystrophy: Eteplirsen for DMD, Ann Neurol, 74, 637, 10.1002/ana.23982 Mendell, 2016, Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy: Eteplirsen in DMD, Ann Neurol, 79, 257, 10.1002/ana.24555 Frank, 2020, Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy, Neurology, 94, e2270, 10.1212/WNL.0000000000009233 Clemens, 2020, Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to Exon 53 skipping: a phase 2 randomized clinical trial, JAMA Neurol, 77, 982, 10.1001/jamaneurol.2020.1264 Clemens, 2022, Long-term functional efficacy and safety of viltolarsen in patients with duchenne muscular dystrophy, J Neuromuscul Dis, 9, 493, 10.3233/JND-220811 Wagner, 2021, Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial, Muscle Nerve, 64, 285, 10.1002/mus.27347